BURLINGTON, Mass., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a global leader in laser- and light-based systems for aesthetic treatments, is pleased to announce the launch of the Palomar Vectus™ Laser – the intelligent choice for fast laser hair removal. "Laser hair removal remains the most popular light-based treatment offered 1 , with nearly one million treatments performed in 2011," said Joseph P. Caruso, President, Chief Executive Officer, and Chairman of the Board. "The Palomar Vectus Laser offers distinct advantages in speed, comfort, and confidence." The Palomar Vectus Laser is a dedicated solution for high-volume hair removal. It provides fast, uniform, permanent hair reduction for the widest range of skin and hair types without sacrificing comfort. The Palomar Vectus Laser features an integrated Skintel™ Melanin Reader, allowing providers to more safely offer laser hair removal treatments with optimized outcomes tailored to each client's skin type, sun exposure habits, and ethnicity. Additionally, the Palomar Vectus Laser uses an intelligent user interface, which allows the provider to quickly select treatment parameters based on the client's hair density, hair color, hair diameter, and Fitzpatrick Skin Type or Skintel Value. "The Palomar Vectus Laser is absolutely superior to all other existing technologies. Its large spot size allows us to treat male backs or female legs within 20 minutes, and its parameters are optimal for minimizing patient discomfort," said Josefina Royo de la Torre, MD, an early user of the Palomar Vectus Laser at Instituto Médico Laser in Madrid, Spain. According to Nicola Otte, MD, of Dermatologikum Hamburg, Hamburg, Germany, "Our patients are impressed by the Skintel Melanin Reader and its ability to customize settings according to their individual skin and hair color. Thanks to the good results and the comfortable treatment, our patients prefer to be treated with the Palomar Vectus Laser."
"No one knows more about light-based hair removal than Palomar," Mr. Caruso continued. "From receiving the first United States Food and Drug Administration clearance for high-powered laser hair removal in 1997, through this launch of the Palomar Vectus Laser, Palomar has demonstrated a unique capability for continually delivering advancements in this must-offer cosmetic application."To learn more about the Palomar Vectus Laser, please visit www.palomarmedical.com/vectus . 1 The American Society for Aesthetic Plastic Surgery, 15 th Annual Cosmetic Surgery National Data Bank Statistics, http://www.surgery.org/media/statistics About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of laser- and light-based systems for aesthetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. As a pioneer of fractional technology, Palomar is an owner of fundamental intellectual property in this area. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the FDA for a new, patented, home-use, fractional laser device for the treatment of periorbital wrinkles. OTC clearance allows these products to be marketed and sold directly to consumers without a prescription. Palomar introduced the PaloVia™ Skin Renewing Laser™ in December 2010. In December 2009, Palomar received the first FDA clearance for the treatment of stretch marks using a fractional non-ablative laser. In September 2010, Palomar received the first FDA clearance for a fractional ablative and fractional non-ablative combination treatment. There are now millions of laser- and light-based aesthetic procedures performed around the world every year in physician offices, clinics, spas, salons, and homes. Palomar is testing many new and exciting applications to further advance the aesthetic market and other surgical applications.
For more information on Palomar and its products, visit Palomar's website at palomarmedical.com.With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2011 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Press Contact: Branden Morris Integrated Marketing Manager (781) 993-2452 email@example.com Investor Relations Contact: Kerry McAnistan Investor Relations Assistant (781) 993-2411 firstname.lastname@example.org